Earnings and full-year outlook beat expectations, led by sharp margin expansion

The quarter cleared a modest market bar by a wide margin. Published expectations were roughly $390.3 million of revenue and $0.63 of EPS; Interface delivered $395.7 million and $0.88, respectively.

(Financial Highlights; Adjustments reconciliation)

The real upside was profitability, not just revenue. Currency-neutral sales grew 3.8%, while orders rose 5.4%, but adjusted gross margin expanded 524 basis points to 45.0%. Price and product mix, manufacturing efficiencies, higher volume, and IEEPA tariff refunds all contributed, so the quarter’s margin strength is partly helped by an item that should not be treated as entirely recurring. (Financial Highlights)

Growth was broad enough to support the beat. The Americas segment grew currency-neutral sales 3.5% and adjusted operating income 24.9%; Europe, Africa and Asia-Pacific grew currency-neutral sales 4.5% and adjusted operating income 97.6%. Healthcare billings rose 19%, while Education and Corporate Office billings each increased 5%, indicating demand was not confined to one product or region. (Segment Results Summary; Management commentary)

Management raised the full-year framework, but the quality of the increase is mixed. Revenue guidance moved only modestly higher, from $1.450–$1.480 billion to $1.455–$1.485 billion, while adjusted gross-margin guidance jumped from 38.8%–39.0% to 40.6%. The company explicitly says the updated outlook includes the Q2 IEEPA tariff refund, making the margin revision look stronger than the underlying recurring upgrade. (Full Fiscal Year 2026 Outlook)

Net read: a clear positive surprise with an important one-time cushion. The EPS and revenue beats were substantial, orders and backlog support continued demand, and the outlook was raised. The main qualification is that tariff refunds helped the unusually large margin step-up, while net debt increased to $122.8 million from $110.3 million at year-end. (Additional Metrics; Cash Flow statement)